PROLONGED PROPIONYL-L-CARNITINE PRETREATMENT OF RABBIT - BIOCHEMICAL, HEMODYNAMIC AND ELECTROPHYSIOLOGICAL EFFECTS ON MYOCARDIUM

被引:23
|
作者
FERRARI, R
DILISA, F
DEJONG, JW
CECONI, C
PASINI, E
BARBATO, R
MENABO, R
BARBIERI, M
CERBAI, E
MUGELLI, A
机构
[1] CNR, CTR MITOCHONDRIAL PHYSIOL, I-35100 PADUA, ITALY
[2] UNIV PADUA, DEPT BIOCHEM, I-35100 PADUA, ITALY
[3] ERASMUS UNIV, CTR THORAX, CARDIOCHEM LAB, 3000 DR ROTTERDAM, NETHERLANDS
[4] UNIV FERRARA, INST PHARMACOL, I-44100 FERRARA, ITALY
关键词
ACTION POTENTIAL; ACYLCARNITINE; HIGH-ENERGY PHOSPHATE; ISOLATED MITOCHONDRIA; LANGENDORFF PERFUSION; PAPILLARY MUSCLE; POSITIVE INOTROPY; MITOCHONDRIAL RESPIRATION;
D O I
10.1016/0022-2828(92)93160-L
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recently it has been reported that prolonged treatment with propionyl-l-carnitine, a carnitine derivative, results in a positive inotropic effect. To gain further insight into its mode of action, we pre-treated 253 rabbits for up to 10 days with daily doses of 1 mmol/kg propionyl-l-carnitine or l-carnitine intraperitoneally, using saline-treated animals as control. Twenty-four hours after the last injection, we isolated papillary muscles for electrophysiological investigations. Whole hearts were used in perfusion experiments for biochemical and hemodynamic measurements. In addition, mitochondria were harvested from these hearts for the analysis of their function. Plasma and cardiac levels of free carnitine, along with plasma short-chain acylcarnitines, increased at least two-fold after treatment with carnitine or its propionyl-ester, with concomitant rises in tissue long-chain acylcarnitine and long-chain acyl-CoA. At the time of animal sacrifice, treatment did not increase plasma or tissue propionyl-l-carnitine content. The studies carried out with perfused hearts and isolated mitochondria failed to show an effect of propionyl-l-carnitine pre-treatment on high-energy phosphate metabolism or respiration. Papillary muscles from animals, treated for 10 days, showed a lengthening of the action potential duration from 63 ± 4 to 102 ± 6 ms (P<0.001) at -10 mV. Perfused hearts from these rabbits displayed positive inotropy, as indicated by an improved pressure development at higher ventricular filling volumes, e.g., from 39 ± 4 to 60 ± 3 mmHg (P<0.05) at 3.6 ml. Pre-treatment with l-carnitine or saline failed to affect the electrophysiological and hemodynamic variables. Thus, prolonged treatment of rabbits with propionyl-l-carnitine, but not with l-carnitine, improved contractility and lengthened action potential duration in isolated muscle preparations. © 1992.
引用
收藏
页码:219 / 232
页数:14
相关论文
共 50 条
  • [11] THE EFFECT OF PROPIONYL-L-CARNITINE ON THE ISCHEMIC AND REPERFUSED INTACT MYOCARDIUM AND ON THEIR DERIVED MITOCHONDRIA
    FERRARI, R
    CECONI, C
    CARGNONI, A
    PASINI, E
    BOFFA, GM
    CURELLO, S
    VISIOLI, O
    CARDIOVASCULAR DRUGS AND THERAPY, 1991, 5 : 57 - 66
  • [12] Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: A review
    Ferrari, R
    Merli, E
    Cicchitelli, G
    Mele, D
    Fucili, A
    Ceconi, C
    CARNITINE: THE SCIENCE BEHIND A CONDITIONALLY ESSENTIAL NUTRIENT, 2004, 1033 : 79 - 91
  • [13] PROTECTIVE EFFECTS OF PROPIONYL-L-CARNITINE DURING ISCHEMIA AND REPERFUSION
    SHUG, A
    PAULSON, D
    SUBRAMANIAN, R
    REGITZ, V
    CARDIOVASCULAR DRUGS AND THERAPY, 1991, 5 : 77 - 84
  • [14] Propionyl-L-carnitine prevents age-related myocardial remodeling in the rabbit
    Orlandi, Augusto
    Francesconi, Arianna
    Ferlosio, Amedeo
    Di Lascio, Antonio
    Marcellini, Marcella
    Pisano, Claudio
    Spagnoli, Luigi Giusto
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 50 (02) : 168 - 175
  • [15] Uptake of [N-methyl-C-11]propionyl-L-carnitine (PLC) in human myocardium
    Cunningham, VJ
    Rosen, SD
    Boyd, H
    Osman, S
    Davenport, RJ
    Gunn, RN
    Pike, VW
    Camici, PG
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1996, 277 (01): : 511 - 517
  • [16] Is propionyl-l-carnitine therapy effective in ulcerative colitis?
    Turner, L. V. B.
    Hamlin, P. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (02) : 315 - 316
  • [17] Study on propionyl-L-carnitine in chronic heart failure
    Anand, IS
    Francis, G
    Maseri, A
    Milazzotto, F
    Pepine, CJ
    Yusuf, S
    Beaufils, P
    Ferrari, R
    Poole-Wilson, PA
    Remme, WJ
    Schlepper, M
    Tavazzi, L
    Visioli, O
    Zarco, P
    Lubsen, J
    Jacono, A
    Kjekshus, J
    Bruzzi, P
    Marubini, E
    Victor, N
    De Giuli, F
    Opasich, C
    Pasini, E
    Klein, W
    Bounhoure, JP
    Cohen, SA
    Page, E
    Zannad, F
    Grosser, K
    Rettig-Sturmer, G
    Ciampricotti, R
    de Boo, J
    den Hartog, F
    Huige, MC
    Kragten, H
    Penn, H
    Visser, F
    Bernardi, D
    Caponnetto, S
    Cardoni, C
    Chiariello, M
    Cobelli, F
    Cucchini, F
    De Ambroggi, L
    Del Citerna, F
    De Ponti, CL
    Giannuzzi, P
    Giordano, A
    Giusti, C
    Lotto, A
    EUROPEAN HEART JOURNAL, 1999, 20 (01) : 70 - 76
  • [18] Effects of propionyl-L-carnitine on cardiac dysfunction in streptozotocin-diabetic rats
    Terada, R
    Matsubara, T
    Koh, N
    Nakamura, J
    Hotta, N
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 357 (2-3) : 185 - 191
  • [19] INHIBITORY EFFECTS OF PROPIONYL-L-CARNITINE ON PLASMA EXTRAVASATION INDUCED BY IRRITANTS IN RODENTS
    AMICOROXAS, M
    CARUSO, A
    CUTULI, VMC
    DEBERNARDIS, E
    LEONARDI, G
    DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, 1993, 19 (05) : 213 - 217
  • [20] EFFECT OF PROPIONYL-L-CARNITINE ON HUMAN ENDOTHELIAL-CELLS
    VANHINSBERGH, VWM
    SCHEFFER, MA
    CARDIOVASCULAR DRUGS AND THERAPY, 1991, 5 : 97 - 106